Cipla Independent Director Naina Lal Kidwai resigns
Mumbai: Cipla has recently announced that Ms. Naina Lal Kidwai, Independent Director of the Company has resigned from the position of Independent Director of the Company with effect from close of business hours of 31st March, 2022.In a letter shared by the Mumbai-based drug firm, the veteran banker noted that she has put in her papers to fulfil several other responsibilities and...
Mumbai: Cipla has recently announced that Ms. Naina Lal Kidwai, Independent Director of the Company has resigned from the position of Independent Director of the Company with effect from close of business hours of 31st March, 2022.
In a letter shared by the Mumbai-based drug firm, the veteran banker noted that she has put in her papers to fulfil several other responsibilities and professional commitments, reports PTI.
"I further confirm that there is no other reason for my resignation as an independent director of the company other than as mentioned in this letter," Kidwai said.
An MBA from Harvard Business School, Ms Naina Lal Kidwai makes regular appearances in listings of international women in business by Fortune and other publications. A recipient of many awards and honours in India, she was awarded the Padma Shri by the Government of India for her contribution to trade and industry.
Ms Kidwai has authored three books; "Survive or Sink - An Action Agenda for Sanitation, Water, Pollution and Green Finance", "Contemporary Banking in India" and "30 Women in Power: Their Voices, Their Stories."
Ms Kidwai possesses rich experience in the areas of banking and finance. She has been a past president of FICCI; is one of the Government of India's representatives on the BRICs Business Council and the INDO-ASEAN Business Council, the Rajasthan Chief Minister's Economic transformation Advisory Council, the Investment Advisory Committee of the Army Group Insurance Fund; on the Governing Board of Lady Shriram College as well as on the Harvard Business School South Asia Advisory Board.
Read also: Cipla plans to launch Molnupiravir under brand name Cipmolnu
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd